NIH Funding: Boost Your Drug-Resistant Bacteria Research
Summary
Is your business developing new treatments or diagnostics for drug-resistant bacteria or parasites? The National Institutes of Health (NIH) is offering funding to accelerate your translational research and bring life-saving technologies to market.
Eligibility
Full Description
Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) invites research applications for projects that support translational research leading to development of therapeutic and diagnostic technologies for drug-resistant bacteria and eukaryotic parasites. Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-AI-09-029, that solicits Phase II and Fast-Track applications under the R44 (SBIR) mechanism.
Funds Available and Anticipated Number of Awards. The NIAID intends to commit $7.3 million in total costs in FY2010 to fund five to ten applications in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.